• Trémedics
    Bioresorbable Stents for Children
    Congenital Heart Disease (CHD) is a disease state in which infants are born with a heart defect.
    Minimal invasive surgical procedures to implant metal stents have been used to reduce mortality/morbidity.
    A goal of Trémedics is to deliver a new generation of polymeric stents, Illusicor™, that resorb within the body.

Who We Are:

Medical Device Company

Trémedics innovates and leads the way for bioresorbable stent technology to improve the lives of children.

Our mission is to develop bioresorbable technology for congenital heart disease. Congenital heart disease patients need devices that resorb within their body as they grow. Currently, metal stents are implanted into these patients and require repeated revascularization procedures to force these stents to grow with the patients. Our technology utilizes a minimal invasive surgery procedure for stent delivery and permits vessel growth as the stent resorbs in the body. Ultimately, this will reduce the number of revascularization procedures

We believe in “filing the technology gap” for this unmet clinical need in congenital heart disease.

Contact Us

Well known and respected


Constant innovation